Clinical Effectiveness, Quality of Life and Costs of Treatment in Transfusion-Dependent Thalassemia Patients Undergoing Iron-Chelating Therapy; Deferiprone

Main Article Content

Sirikorn Pratoombarn
Sukit Roongapinun
Saranyapin Potikanond
Pimlak Charoenkwan
Adisak Tantiworawit
Noppamas Rojanasthien

Abstract

A major complication of long-term blood transfusion in thalassemia patients is a serious iron overload. Excessive iron deposits in major organs and eventually results in organ damage. Deferiprone (DFP) is an effective oral iron chelator that promotes iron excretion and prevents the progression of iron accumulation assessed by serum ferritin levels. To evaluate the overall impact of DFP in transfusion-dependent thalassemia patients, this study aimed to determine the clinical effectiveness, health-related quality of life (HRQOL) and treatment costs of DFP. A cross-sectional study was conducted among 50 transfusion-dependent thalassemia patients who received DFP at Maharaj Nakorn Chiang Mai Hospital. The data of clinical effectiveness and costs of treatment were collected from the questionnaire and retrospectively reviewed over a 12-month period from medical records and hospital database. HRQOL was assessed by using the questionnaire, EQ-5D-3L (Thai version). The result showed the mean serum ferritin level (µg/L) at baseline and final level of 1367±935 and 1386±541, respectively. The mean EQ-5D-3L and VAS scores were 0.80±0.16 and 81.9±14.0, respectively. The adherence to treatment was found to be poor and the common adverse events reported were headache, back pain, arthralgia, fever, elevated liver enzyme, nausea/vomiting, abdominal pain and diarrhea. The total annual direct costs of treatment were estimated to be 54,000 Thai Baht (THB)/patient. In conclusion, DFP was effective in maintaining serum ferritin level in transfusion-dependent thalassemia patients with reasonable costs of treatment. Although patients’ HRQOL assessments were favorable, adherence to treatment was poor with more adverse events reported.

Downloads

Download data is not yet available.

Article Details

Section
Research Articles

References

Rund D, Rachmilewitz E. β-Thalassemia. New England Journal of Medicine. 2005;353(11):1135-46.

Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the clinical management of thalassaemia. 2nd rev ed. Nicosia: Thalassaemia International Federation; 2008.

Anderson GJ. Mechanisms of iron loading and toxicity. American Journal of Hematology. 2007;82(S12):1128-31.

Andrews NC. Disorders of Iron Metabolism. New England Journal of Medicine. 1999;341(26):1986-95.

Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfusion. 2012;10(4):411-22.

Oemar M, Oppe M. EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument version 5.0 [Internet]. Rotterdam: EuroQol Group; 2013 [cited 2015 Feb 20]. Available from: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2013_v5.0_October_2013.pdf.

Tongsiri S. The Thai population-based preference scores for EQ-5D health states [Doctoral dissertation]. London: University of London; 2009.

Vichinsky E, Levine L, Bhatia S, Bojanowski J, Coates T, Foote D, et al. Standards of Care Guidelines for Thalassemia 2012 [Internet]. California: Children's Hospital & Research Center Oakland; 2012 [cited 2013 Aug 26]. Available from: http://thalassemia.com/documents/SOCGuidelines2012.pdf.

Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology. 2000;108(2):305-12.

Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-7.

Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, et al. Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. American Journal of Hematology. 2013;88(4):251-60.

Sakthong P, Kasemsup V. Health Utility Measured with EQ-5D in Thai Patients Undergoing Peritoneal Dialysis. Value in Health.15(1):S79-S84.

Sakthong P, Schommer JC, Gross CR, Prasithsirikul W, Sakulbumrungsil R. Health Utilities in Patients with HIV/AIDS in Thailand. Value in Health. 2009;12(2):377-84.

Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Current Medical Research and Opinion. 2008;24(7):1905-17.